Metabolic
Cagrilintide
Cagrilintide is a long-acting acylated analog of the pancreatic hormone amylin, designed for once-weekly subcutaneous administration. It promotes satiety by acting on amylin receptors in the area postrema, slowing gastric emptying and suppressing postprandial glucagon secretion. It is being developed in combination with semaglutide (CagriSema) for enhanced weight loss outcomes.
Quick Facts
Also known asAM833
CategoryMetabolic
Half-life~8 days
Routessubcutaneous
Molecular weight4409.01 Da
Chain length37 amino acids
SequenceLys-Cys-Asn-Thr-Ala-Thr-Cys-Ala-Thr-Gln-Arg-Leu-Ala-Asn-Phe-Leu-Val-His-Ser-Ser-Asn-Asn-Phe-Gly-Pro-Ile-Leu-Pro-Pro-Thr-Asn-Val-Gly-Ser-Asn-Thr-Tyr-NH2
FDA statusNot approved
Storage2-8°C (refrigerated). Reconstituted: 42 days.
Dosing Protocols
| Goal | Dose | Frequency | Route | Cycle | Notes |
|---|---|---|---|---|---|
| Weight Loss (Monotherapy) | 2.4 mg | 1x/week | subcutaneous | Continuous | 2.4mg once weekly subcutaneous injection. Continuous use. Same day each week. Evening injection may reduce nausea. |
| Weight Loss (CagriSema Combination) | 2.4 mg | 1x/week | subcutaneous | Continuous | 2.4mg cagrilintide + 2.4mg semaglutide once weekly. Up to 22.7% weight loss in REDEFINE 1 trial. |
| Type 2 Diabetes | 2.4 mg | 1x/week | subcutaneous | Continuous | 2.4mg weekly with metformin. 15.7% weight loss with 73.5% achieving HbA1c <=6.5%. |
| Dose Escalation | 250 mcg | 1x/week | subcutaneous | 16 weeks | Start 0.25mg, escalate weekly: 0.25 -> 0.5 -> 1.0 -> 1.7 -> 2.4mg. 16-week titration period. |
Protocols shown are for informational purposes only. Consult a healthcare provider before starting any peptide protocol.
Track Your Cagrilintide Protocol
Log doses, manage vial inventory, set injection reminders, and visualize blood concentration levels.
Start Tracking — FreeCommon Questions
What is the typical dose of Cagrilintide?
A common dose for Cagrilintide is 2.4 mg 1x/week via subcutaneous. 2.4mg once weekly subcutaneous injection. Continuous use. Same day each week. Evening injection may reduce nausea.
What is the half-life of Cagrilintide?
The half-life of Cagrilintide is approximately ~8 days. This determines how long the peptide remains active in your body and influences dosing frequency.
How should I store Cagrilintide?
Store Cagrilintide at 2-8°C (refrigerated). Investigational compound in late-stage clinical trials. Acylated structure provides extended duration of action similar to semaglutide. Once reconstituted, use within 42 days.
Is Cagrilintide FDA approved?
Cagrilintide is not FDA approved and is available for research purposes only. It has not been evaluated by the FDA for safety or efficacy in humans.
References
- Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity - Garvey et al. (2025) (article)
- Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes - Davies et al. (2025) (article)
- Efficacy and safety of co-administered cagrilintide 2.4mg with semaglutide 2.4mg in type 2 diabetes - Frias et al. (2023) (article)
- Once-weekly cagrilintide for weight management - Lau et al. (2021) (pubmed)
- Safety, tolerability, pharmacokinetics of concomitant administration of cagrilintide with semaglutide - Enebo et al. (2021) (article)
- Development of Cagrilintide, a Long-Acting Amylin Analogue - Kruse et al. (2021) (article)
- Structural and dynamic features of cagrilintide binding to calcitonin and amylin receptors - Cao et al. (2025) (article)
- Cagrilintide is not associated with clinically relevant QTc prolongation - Gabe et al. (2024) (article)
- Efficacy and Safety of Cagrilintide meta-analysis - Dutta et al. (2024) (pubmed)
- Cagrilintide: Long-Acting Amylin Analog for Obesity Treatment - D'Ascanio et al. (2024) (article)